WCLC 2024 – Diego Kauffmann-Guerrero

You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.

More Information
Unblock content Accept required service and unblock content

Diego Kauffmann-Guerrero provides insights into bispecific antibody treatments, an emerging class of therapeutics for small-cell lung cancer and neuroendocrine tumors of the lung. He highlights trials involving BiTEs in combination with other agents and offers an outlook on new treatment options for small-cell lung cancer expected to emerge in the coming years.

Here is the full WCLC 2024 report.